Argos Therapeutics, Inc. is developing fully personalized immunotherapies that target unique features of a patient’s disease. This new generation of personalized therapeutics trains the immune system to recognize and attack diseases. Argos’ scientific leadership in RNA-loaded dendritic cells and advanced manufacturing processes provide a platform that we believe can tackle a wide range of cancers and infectious diseases.
Argos Therapeutics Reports Third Quarter 2014 Financial Results and Operational Highlights
Philippe Van Holle Joins Argos Therapeutics Board of Directors
Argos Therapeutics to Present at the Stifel 2014 Healthcare Conference